Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review (Q28294064)

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Evolution of the health economics of cervical cancer vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

The causal relation between human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Economic evaluation of human papillomavirus vaccination in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Modeling cervical cancer prevention in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Human papillomavirus vaccine introduction--the first five years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

inferred from DOI database lookup

7 January 2021

based on heuristic

Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

WHO Guide for standardisation of economic evaluations of immunization programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Health and economic implications of HPV vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Mathematical models of cervical cancer prevention in the Asia Pacific region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.060

10.1016/J.VACCINE.2013.06.060

7 January 2021

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23830973

1 reference

Consolidated OpenCitations Corpus – April 2017